Gilead’s HIV drug patent battle with CDC continues with government appeal

The US government is appealing a jury’s decision that granted Gilead a major win in a patent fight over the company’s blockbuster HIV treatments Truvada and Descovy.

Lawyers for the government last Friday filed their appeal following a defeat to Gilead in May 2023, when six jurors found that the US had not proven patients and physicians infringed certain patents by using Truvada and Descovy for PrEP and that the patents are invalid.

But in March, District Judge Maryellen Noreika partially walked back Gilead’s jury win, ruling that the CDC patents were infringed. Still, Noreika kept the original jury decision that the patents were invalid.

The Delaware decision “upheld an earlier jury verdict in favor of Gilead that the U.S. government’s patents are invalid,” Gilead told Endpoints News in an emailed statement on Monday. “The Court’s decision and jury verdict recognized Gilead’s commitment to transforming the lives…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks